Comparing two antibiotics for drug-resistant infections
Treatments studied
Part of Infections clinical trials.
This trial tests two different antibiotic combinations (ampicillin/sulbactam and cefoperazone/sulbactam) to see which works better against a type of bacteria (Acinetobacter baumannii) that is resistant to many other drugs. It is for critically ill patients with signs of sepsis.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 21 years old or older.
- You have signs and symptoms of sepsis (a severe response to infection).
- You have a positive culture showing an infection with carbapenem-resistant Acinetobacter baumannii (a bacteria that is hard to treat).
- You have not already been treated with sulbactam-based antibiotics for this infection.
- You do not have a known allergy to ampicillin/sulbactam or cefoperazone/sulbactam.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests which of two antibiotic combinations works better at clearing infections caused by multi-drug-resistant bacteria in adults, including those with weakened immune systems. It aims to find a more effective treatment option.
This trial studies whether cefiderocol plus ampicillin-sulbactam works better than colistin (sometimes with meropenem) for serious infections caused by carbapenem-resistant Acinetobacter baumannii (a hard-to-treat germ). It may help by finding a more effective antibiotic plan for people with these severe hospital-acquired infections.
This trial compares different treatment options for patients in the ICU who have a resistant bacterial infection called Acinetobacter baumannii. If you have this infection after surgery, the study aims to find the best way to treat it.
This study tests different antibiotic combinations for severe infections caused by hard-to-treat Gram-negative bacteria (like Pseudomonas or Acinetobacter). The goal is to find the best treatment for bloodstream infections or pneumonia that started in the hospital.
This study tracks hospitalized patients receiving a specific antibiotic combination (sulbactam-durlobactam) to treat a serious, hard-to-treat bacterial infection called CRAB. Researchers want to understand how well this treatment works in real-world hospital settings.
This trial compares two common antibiotics, meropenem and piperacillin/tazobactam, to see which works better for adults with sepsis who are critically ill. It aims to help doctors choose the best treatment for serious infections.
Hear when a new Acinetobacter Baumannii Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.